alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     THIS SCHEDULE  CONTAINS SUMMARY  FINANCIAL  INFORMATION  EXTRACTED FROM THE
     ACCOMPANYING  FINANCIAL  STATEMENTS  AND IS  QUALIFIED  IN ITS  ENTIRETY BY
     REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>                                   1,000

<S>                              <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 APR-03-2000
<PERIOD-END>                                   JUL-02-2000
<CASH>                                              27,848
<SECURITIES>                                        27,281
<RECEIVABLES>                                       41,200
<ALLOWANCES>                                         2,554
<INVENTORY>                                         25,897
<CURRENT-ASSETS>                                   134,418
<PP&E>                                             675,494
<DEPRECIATION>                                     398,626
<TOTAL-ASSETS>                                     430,087
<CURRENT-LIABILITIES>                              294,952
<BONDS>                                                  0
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                               668
<OTHER-SE>                                          70,735
<TOTAL-LIABILITY-AND-EQUITY>                       430,087
<SALES>                                             83,468
<TOTAL-REVENUES>                                    83,468
<CGS>                                               73,534
<TOTAL-COSTS>                                       73,534
<OTHER-EXPENSES>                                    13,956
<LOSS-PROVISION>                                        (8)
<INTEREST-EXPENSE>                                   7,457
<INCOME-PRETAX>                                    (10,115)
<INCOME-TAX>                                           450
<INCOME-CONTINUING>                                (10,246)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                      3,772
<CHANGES>                                                0
<NET-INCOME>                                        (6,474)
<EPS-BASIC>                                          (0.10)
<EPS-DILUTED>                                        (0.10)



</TABLE>
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   Year
<FISCAL-YEAR-END>                              Dec-31-1996
<PERIOD-END>                                   Dec-31-1997
<CASH>                                         57,320
<SECURITIES>                                   751
<RECEIVABLES>                                  9,727
<ALLOWANCES>                                   (1,673)
<INVENTORY>                                    2,109
<CURRENT-ASSETS>                               74,957
<PP&E>                                         51,182
<DEPRECIATION>                                 (4,608)
<TOTAL-ASSETS>                                 142,112
<CURRENT-LIABILITIES>                          52,804
<BONDS>                                        39,495
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       85
<OTHER-SE>                                     49,728
<TOTAL-LIABILITY-AND-EQUITY>                   142,112
<SALES>                                        0
<TOTAL-REVENUES>                               186,275
<CGS>                                          0
<TOTAL-COSTS>                                  171,158
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             114
<INCOME-PRETAX>                                15,231
<INCOME-TAX>                                   6,306
<INCOME-CONTINUING>                            8,925
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                15,969
<CHANGES>                                      0
<NET-INCOME>                                   24,894
<EPS-PRIMARY>                                  4.11
<EPS-DILUTED>                                  3.46



</TABLE>
#### § 20.114 Data and information submitted pursuant to cooperative quality assurance agreements.

Data and information submitted to the Food and Drug Administration pursuant to a cooperative quality assurance agreement shall be handled in accordance with the rules established in § 20.111.
[Federal Register Volume 75, Number 7 (Tuesday, January 12, 2010)]
[Proposed Rules]
[Page 1567]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-380]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Defense Acquisition Regulations System

[DFARS Case 2009-D012]

48 CFR Parts 225 and 252


Defense Federal Acquisition Regulation Supplement; Foreign 
Participation in Acquisitions in Support of Operations in Afghanistan

AGENCY: Department of Defense (DoD).

ACTION: Proposed rule; correction of comment date.

-----------------------------------------------------------------------

SUMMARY: DoD is proposing to amend the Defense Federal Acquisition 
Regulation Supplement (DFARS) to implement: Waiver of the section 
302(a) of the Trade Agreements Act of 1979, as amended, which prohibits 
acquisitions of products or services from non-designated countries, in 
order to allow acquisition from the nine South Caucasus/Central and 
South Asian (SC/CASA) states; and Determination of inapplicability of 
the Balance of Payments Program evaluation factor to offers of products 
(other than arms, ammunition, or war materials) from the SC/CASA states 
to support operations in Afghanistan. The end of the comment period was 
erroneously published as March 9, 2009, rather than March 9, 2010.

DATES: Comment date: Comments on the proposed rule published January 6, 
2010 (75 FR 832), should be submitted in writing to the address shown 
below on or before March 9, 2010.

ADDRESSES: You may submit comments, identified by DFARS Case 2009-D012, 
using any of the following methods:
    <bullet> Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the instructions for submitting comments.
    <bullet> E-mail: <a href="/cdn-cgi/l/email-protection#0c686a6d7e7f4c637f6822616560"><span class="__cf_email__" data-cfemail="a0c4c6c1d2d3e0cfd3c48ecdc9cc">[email protected]</span></a>. Include DFARS Case 2009-D012 in the 
subject line of the message.
    <bullet> Fax: (703) 602-0305.
    <bullet> Mail: Defense Acquisition Regulations System, Attn: Ms. 
Amy Williams, OUSD (AT&L) DPAP (DARS), IMD 3D139, 3062 Defense 
Pentagon, Washington, DC 20301-3062.
    <bullet> Hand Delivery/Courier: Defense Acquisition Regulations 
System, Crystal Square 4, Suite 200A, 241 18th Street, Arlington, VA 
22202-3402.
    Comments received generally will be posted without change to http://www.regulations.gov, including any personal information provided.

FOR FURTHER INFORMATION CONTACT: Ms. Amy Williams, (703) 602-0328.

SUPPLEMENTARY INFORMATION: 

A. Background

    On January 6, 2010, DoD published a proposed rule in the Federal 
Register (75 FR 832). The comment date is being corrected from March 9, 
2009, to March 9, 2010.

Amy G. Williams,
Editor, Defense Acquisition Regulations System.
[FR Doc. 2010-380 Filed 1-11-10; 8:45 am]
BILLING CODE 5001-08-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
###### Editorial Note on Part 314

#### Editorial Note:

Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

#### § 314.600 Scope.

This subpart applies to certain new drug products that have been studied for their safety and efficacy in ameliorating or preventing serious or life-threatening conditions caused by exposure to lethal or permanently disabling toxic biological, chemical, radiological, or nuclear substances. This subpart applies only to those new drug products for which: Definitive human efficacy studies cannot be conducted because it would be unethical to deliberately expose healthy human volunteers to a lethal or permanently disabling toxic biological, chemical, radiological, or nuclear substance; and field trials to study the product's effectiveness after an accidental or hostile exposure have not been feasible. This subpart does not apply to products that can be approved based on efficacy standards described elsewhere in FDA's regulations (e.g., accelerated approval based on surrogate markers or clinical endpoints other than survival or irreversible morbidity), nor does it address the safety evaluation for the products to which it does apply.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE POPE &
TALBOT, INC. CONSOLIDATED CONDENSED FINANCIAL STATEMENTS FOR THE SIX MONTH
PERIOD ENDED JUNE 30, 1998, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                          25,489
<SECURITIES>                                    37,603
<RECEIVABLES>                                   66,567
<ALLOWANCES>                                         0
<INVENTORY>                                     73,154
<CURRENT-ASSETS>                               215,267
<PP&E>                                         438,089
<DEPRECIATION>                                 190,453
<TOTAL-ASSETS>                                 476,230
<CURRENT-LIABILITIES>                           66,048
<BONDS>                                        140,568
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        13,972
<OTHER-SE>                                     170,224
<TOTAL-LIABILITY-AND-EQUITY>                   476,230
<SALES>                                        209,995
<TOTAL-REVENUES>                               209,995
<CGS>                                          215,616
<TOTAL-COSTS>                                  215,616
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               4,108
<INCOME-PRETAX>                                (21,737)
<INCOME-TAX>                                    (6,403)
<INCOME-CONTINUING>                            (15,334)
<DISCONTINUED>                                  27,074
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    13,355
<EPS-PRIMARY>                                      .99
<EPS-DILUTED>                                      .99
        

</TABLE>
<PAGE>   1


                                                                   EXHIBIT 10.38

                                                              Seafirst Bank 
                                                              A BankAmerica
                                                              Company 
                                                              701 Fifth Avenue,
                                                              16th Floor
                                                              Seattle WA, 98104 
                                                              Fax 206/358-0971
                                                              206/358-0101

                                                              DORA A. BROWN
                                                              VICE PRESIDENT
                                                              Seafirst Agency 
                                                              Services



December 23, 1998

Scott Stewart
Spacelabs Medical, Inc.                      Fax:  425-885-4877
15220 NE 40th Street
Redmond, WA  98073-9713

RE:  Spacelabs Medical, Inc., a California corporation ("Company")
     Amended and Restated Loan Agreement dated July 16, 1997 ("Loan Agreement")

Dear Scott:

Bank of America National Trust and Savings Association dba Seafirst Bank, as
Agent for and with consent of the Lenders, agrees to the modification of Section
5.11 of the Loan Agreement, whereby the Funded Debt to EBITDA Ratio will not
exceed 3.8:1 for the fiscal quarter ending December 31, 1998, only. The Funded
Debt to EBITDA Ratio maximum of 3.5:1 will resume with the Company's fiscal
quarter ending March 31, 1999 and every quarter thereafter. All other terms and
conditions to the Loan Agreement remain unchanged, unless otherwise agreed to in
writing by the Agent and the Lenders.

Please call me it I can be of further assistance.

Sincerely,

Seafirst Bank, as Agent

Dora Brown
V.P./Senior Agency Officer
Exhibit
      32.2








CERTIFICATION
      PURSUANT TO


18
      U.S.C.
      SECTION 1350,


AS
      ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002











In
      connection with the Quarterly Report of Tonga Capital Corp (the "Company")
      on
      Form 10-QSB for the period ending March 31, 2007 as filed with the Securities
      and Exchange Commission on the date hereof (the "Report"). I, Stuart C. Cater,
      Chief Financial Officer of the company, certify, pursuant to 18 USC Section
      1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
      that
      to the best of my knowledge and belief.





(1)
      The
      Report fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2)
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of Operations of the Company.











/s/
      Stuart C.
      Cater


Stuart
      C.
      Cater, Chief Financial Officer


Dated:
      May 9, 2007
<PAGE>

                                                                  EXHIBIT 10.9.1

                             FIRST AMENDMENT TO THE

                          MASTER TAX SHARING AGREEMENT

      This FIRST AMENDMENT TO THE MASTER TAX SHARING AGREEMENT is entered into
as of June 10, 2004 ("Amendment"), by and among Westcorp (FEIN No. 53-0308535)
and each of the subsidiaries subscribed thereto.

                                    RECITALS

      WHEREAS, the parties have entered into a Master Tax Sharing Agreement,
effective as of the first day of the consolidated return year beginning January
1, 2004 ("Agreement");

      WHEREAS, WFS Financial Auto Loans, Inc., a Member of the Agreement, merged
into its parent company, WFS Financial Inc on March 19, 2004;

      WHEREAS, the parties desire to amend the Agreement to remove WFS Financial
Auto Loans, Inc. as a Member; and

      NOW, THEREFORE, in consideration of the mutual covenants and promises
contained in the Agreement and in this Addendum and for other good and
sufficient consideration, the Agreement is amended as follows:

      1.    WFS Financial Auto Loans, Inc. (33-0149603) is removed as a Member
            to the Agreement effective March 19, 2004.

      Except as amended specifically herein, all terms and conditions of the
Agreement, shall remain in full force and effect.

      All capitalized terms not herein defined shall have the same meaning as
set forth in the Agreement.

      IN WITNESS WHEREOF, the undersigned have executed this Amendment on the
date set forth below to be retroactive to and effective as of March 19, 2004.

WESTCORP

By:                                             Date: _________, 2004
    ______________________________________
     Thomas A. Wolfe, President

WFS FINANCIAL INC

By:                                            Date: _________, 2004
    _____________________________________
     Shelley Chase, Senior Vice President
     & Director of Tax
EX. 34.12

(logo) Grant Thornton

Report of Independent Registered Public Accounting Firm
Regulation AB Item 1122 Special Servicing Platform

Grant Thornton LLP
1717 Main Street, Suite 1500
Dallas, TX 75201-4667

T 214.561.2300
F 214.561.2370
GrantThornton.com
linkd.in/GrantThorntonUS
twitter.com/GrantThorntonUS

Board of Directors and Shareholders
Situs Holdings, LLC

     We have examined Situs Holdings, LLC, (the "Company") compliance with the
servicing criteria set forth in Item 1122(d) of the U.S. Securities and
Exchange Commission's Regulation AB for the Special Servicing Platform (the
"Platform") described in the accompanying Management's Certification Regarding
Compliance with Applicable Servicing Criteria ("Management's Report") as of and
for the year ended December 31, 2013, excluding criteria 1122(d)(1)(iii),
1122(d)(2)(ii), 1122(d)(3)(i-iv),1122(d)(iv), 1122(d)(4)(v), and 1122(d)(4)(ix
-xv), which management has determined are not applicable to the activities
performed by the Company with respect to the Platform. The Platform consists of
the asset-backed transactions and securities defined by management in
Management's Report. Management is responsible for the Company's compliance
with the applicable servicing criteria. Our responsibility is to express an
opinion on the Company's compliance with the applicable servicing criteria for
the Platform based on our examination .

Our examination was conducted in accordance with the standards of the Public
Company Accounting Oversight Board (United States) and, accordingly, included
examining, on a test basis, evidence about the Company's compliance with the
applicable servicing criteria for the Platform and performing such other
procedures as we considered necessary in the circumstances. Our examination
included testing selected asset-backed transactions and securities constituting
the Platform and evaluating whether the Company performed servicing activities
related to those transactions and securities in compliance with the applicable
servicing criteria for the period covered by this report. Accordingly, our
testing may not have included servicing activities related to each asset-backed
transaction or security constituting the Platform. Further, our examination was
not designed to detect material noncompliance that may have occurred prior to
the period covered by this report and that may have affected the Company's
servicing activities during the period covered by this report. We believe
that our examination provides a reasonable basis for our opinion. Our
examination does not provide a legal determination on the Company's compliance
with the applicable servicing criteria.

In our opinion, management's assertion that Situs Holdings, LLC complied with
the aforementioned applicable servicing criteria as of and for the year ended
December 31, 2013 for the Special Servicing Platform is fairly stated, in all
material respects.


/s/ Grant Thornton LLP
Dallas, Texas
April 24, 2014

Grant Thornton LLP
U.S. member firm of Grant Thornton International Ltd
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.309 Acetophenetidin (phenacetin)-containing preparations; necessary warning statement. ( a ) In 1961, the Food and Drug Administration, pursuant to its statutory responsibility for the safety and effectiveness of drugs shipped in interstate commerce, began an active investigation of reports of possible toxic effects and renal damage due to misuse of the drug acetophenetidin. This study led to the decision that there was probable cause to conclude that misuse and prolonged use of the drug were in fact responsible for kidney lesions and disease. The Commissioner of Food and Drugs, in December 1963, appointed an ad hoc Advisory Committee of Inquiry on Possible Nephrotoxicity Associated With the Abuse of Acetophenetidin (Phenacetin)-Containing Preparations. This committee, composed of scientists in the fields of pharmacology and medicine, on April 23, 1964, submitted its findings and conclusions in the matter and recommended that all acetophenetidin (phenacetin)-containing preparations bear a warning as provided in section 502(f)(2) of the Federal Food, Drug, and Cosmetic Act.
( b ) On the basis of the studies made by the Food and Drug Administration and the report of the Advisory Committee, the Commissioner of Food and Drugs has concluded that it is necessary for the protection of users that the label and labeling of all acetophenetidin (phenacetin)-containing preparations bear a warning statement to the following effect: “Warning—This medication may damage the kidneys when used in large amounts or for a long period of time. Do not take more than the recommended dosage, nor take regularly for longer than 10 days without consulting your physician.”
### Surface water supply of the United States, 1922, Part III, Ohio River basin

By: Water Resources Division, U.S. Geological Survey

                            https://doi.org/10.3133/wsp543

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
§ 346.1 Scope. ( a ) An over-the-counter anorectal drug product in a form suitable for external (topical) or intrarectal (rectal) administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this part and each general condition established in § 330.1 of this chapter.
( b ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 212 unless otherwise noted.
[No. 37829-5-I.

Division One.

January 12, 1998.]

#### Ronald Corcoran, *Respondent,*v. Westinghouse Electric Corporation, et al., *Appellants.*

Appeal from a judgment of the Superior Court for King County, No. 93-2-13671-4, Steven G. Scott, J., entered November 15, 1995. *Affirmed*by unpublished opinion per Webster, J., concurred in by Coleman and Ellington, JJ.
###### Editorial Note on Part 369

#### Editorial Note:

Nomenclature changes to part 369 appear at 69 FR 13717, Mar. 24, 2004.

#### § 369.4 Warnings suggested for drugs by formal or informal statements of policy.

The warning and caution statements included in subpart B of this part in no way affect any warning statement suggested for such drugs or devices by any statement of policy or interpretation in subchapter C of this chapter.

[39 FR 11745, Mar. 29, 1974, as amended at 40 FR 13496, Mar. 27, 1975]